DigestRedComo funciona
Red
/
Empresas
De
No verificado

Deciphera Pharmaceuticals Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaOncologíaSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
06/12/2025
Multimedia
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Eventos
Industria
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
Fuente
Deciphera Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
17/11/2025
Multimedia
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Deciphera Announces the Opening of a New Office in Zug, Switzerland
Fuente
Deciphera Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
12/11/2025
Multimedia
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025
Fuente
Deciphera Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
18/10/2025
Multimedia
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Ferias y Congresos
Industria
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
Fuente
Deciphera Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
17/09/2025
Oncología
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Industria
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Fuente
Deciphera Pharmaceuticals Inc.
Editor
Business Wire
1.00
0
14/02/2025
Multimedia
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Oncología
Industria
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Fuente
Deciphera Pharmaceuticals Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0